Life sciences junior is capitalizing on a healthier eating trend
SmallCapPower | January 11, 2017: On January 26, 2016, SmallCapPower interviewed AlphaNorth Asset Management Associate Portfolio Manager Tina Byers at the AlphaNorth Capital Conference in Nassau, Bahamas (watch the interview), who mentioned a life sciences junior that she liked at the time. Nearly a year later, the stock’s value has powered about 170% higher to its current price of $0.135, even closing as high as $0.20 a share in early October.
The company she favoured at the time, Avivagen Inc. (TSXV: VIV), is focused on antibiotic alternatives that are added to livestock feeds. Anyone who watches television has probably seen commercials for fast-food restaurants that are promoting antibiotic-free meat in their food. Industry giants such as McDonald’s and Chipotle Mexican Grill have really moved away from antibiotics, a trend that will likely continue and become the norm. In her interview, Ms. Byers said she believes this to be a large and growing market.
Avivagen has a proprietary product that’s all natural and safe, so that you get the same yield in your feedstock but it’s heathier for the individual, according to Ms. Byers. During 2016, Avivagen received approval for use of its product in all species in the Philippines and announced its first industrial-scale sale in that country, as well as signing commercial partnerships in both the Philippines and China. For 2017, the Company hopes to execute further commercial and trial alliances in Asia and elsewhere, secure registration in more nations, develop protocols for use in new species, and establish proof of concept for human applications.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
The company she favoured at the time, Avivagen Inc. (TSXV: VIV), is focused on antibiotic alternatives that are added to livestock feeds. Anyone who watches television has probably seen commercials for fast-food restaurants that are promoting antibiotic-free meat in their food. Industry giants such as McDonald’s and Chipotle Mexican Grill have really moved away from antibiotics, a trend that will likely continue and become the norm. In her interview, Ms. Byers said she believes this to be a large and growing market.
